IP Library Granted Patent US 7,736,874
Granted Patent B2
US 7,736,874 · App. 10/960,510 · Granted Jun 15, 2010

Methods for cloning amplified nucleic acid molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,736,874
App. No.
10/960,510
Granted
Jun 15, 2010
Kind
B2
Abstract

The present invention is directed generally to methods facilitating the cloning of nucleic acid molecules. In particular, the invention relates to the use of polymerase inhibitors, including but not limited to anti-polymerase antibodies (such as anti-Taq antibodies) and fragments thereof, to inactivate residual polymerase activity remaining after the amplification (particularly via PCR) of a target nucleic acid molecule. The invention further provides compositions, particularly storage-stable compositions, comprising one or more components, such as one or more restriction endonucleases and one or more polymerase inhibitors, that are useful in cloning amplified or synthesized nucleic acid molecules by the above-described methods. The invention also relates to nucleic acid molecules produced by these methods, and to genetic constructs (such as vectors) and host cells comprising these nucleic acid molecules.

Claims (12)

1. A method for cloning one or more nucleic acid molecules having a first 3′ overhang into one or more vectors having a second 3′ overhang, comprising:

(a) forming a mixture comprising the one or more nucleic acid molecules having the first 3′ overhang, the one or more vectors having the second 3′ overhang and one or more antibodies or fragments thereof which inhibit a polymerase; and

(b) ligating the nucleic acid molecules having the first 3′ overhang to the one or more vectors having the second 3′ overhang to form one or more genetic constructs, thereby cloning the one or more nucleic acid molecules having the first 3′ overhang.

2. The method of claim 1 , wherein the first 3′ overhang is a dA overhang.

3. The method of claim 1 , wherein the second 3′ overhang is a dT overhang.

4. The method of claim 1 , wherein the one or more antibodies or fragments thereof are anti-Taq antibodies.

5. A method of ligating amplified or synthesized nucleic acid molecules having a first 3′ overhang into one or more vectors having a second 3′ overhang, comprising:

(a) forming a mixture comprising the amplified or synthesized nucleic acid molecules having the first 3′ overhang, one or more vectors having the second 3′ overhang, and one or more antibodies or fragments thereof which inhibit a polymerase; and

(b) ligating the amplified or synthesized nucleic acid molecules having the first 3′ overhang to the one or more vectors having the second 3′ overhang to form one or more genetic constructs.

6. The method of claim 5 , wherein the first 3′ overhang is a dA overhang.

7. The method of claim 5 , wherein the second 3′ overhang is a dT overhang.

8. The method of claim 5 , wherein the one or more antibodies or fragments thereof are anti-Taq antibodies.

Assignments (4)
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
CHANGE OF NAME Recorded Nov 4, 2009
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023456/0934 →
CHANGE OF NAME Recorded Apr 13, 2009
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 022539/0167 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →